Work

Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer

Year: 2021
Type: article
Study design: Observational Study
Abstract: KRAS is the most commonly mutated oncogene in NSCLC and development of direct KRAS inhibitors has renewed interest in this molecular variant. Different KRAS mutations may represent a unique biologic context with different prognostic and therapeutic impact. We sought to characterize genomic landscapes of advanced, KRAS-mutated non–small cell lung cancer (NSCLC) in a large national cohort to help guide future therapeutic development. Molecular profiles of 17,095 NSCLC specimens were obtained using DNA next-generation sequencing of 592 genes (Caris Life Sciences) and classified on the basis of presence and subtype of KRAS mutations. Co-occurring genomic alterations, tumor mutational burden (TMB), and PD-L1 expression [22C3, tumor proportion score (TPS) score] were analyzed by KRAS mutation type. Across the cohort, 4,706 (27.5%) samples harbored a KRAS mutation. The most common subtype was G12C (40%), followed by G12V (19%) and G12D (15%). The prevalence of KRAS mutations was 37.2% among adenocarcinomas and 4.4% in squamous cell carcinomas. Rates of high TMB (≥10 mutations/Mb) and PD-L1 expression varied across KRAS mutation subtypes. KRAS G12C was the most likely to be PD-L1 positive (65.5% TPS ≥ 1%) and PD-L1 high (41.3% TPS ≥ 50%). STK11 was mutated in 8.6% of KRAS wild-type NSCLC but more frequent in KRAS-mutant NSCLC, with the highest rate in G13 (36.2%). TP53 mutations were more frequent in KRAS wild-type NSCLC (73.6%). KRAS mutation subtypes have different co-occurring mutations and a distinct genomic landscape. The clinical relevance of these differences in the context of specific therapeutic interventions warrants investigation.
Authors: Julia Judd(Conceptualization, Investigation, Visualization, Writing – original draft, Writing – review & editing), Nagla Abdel Karim(Conceptualization, Investigation, Writing – review & editing), Hina Khan(Conceptualization, Investigation, Writing – review & editing), Abdul Rafeh Naqash(Investigation, Writing – review & editing), Yasmine Baca(Data curation, Formal analysis, Software, Visualization), Joanne Xiu(Data curation, Formal analysis, Software, Validation, Visualization), Ari M. VanderWalde(Investigation, Writing – review & editing), Hirva Mamdani(Investigation, Writing – review & editing), Luis E. Raez(Investigation, Writing – review & editing), Misako Nagasaka(Investigation, Writing – review & editing), Sachin Gopalkrishna Pai(Investigation, Writing – review & editing), Mark A. Socinski(Investigation, Writing – review & editing), Jorge J. Nieva(Investigation, Writing – review & editing), Chul Kim(Investigation, Writing – review & editing), Antoinette J. Wozniak(Investigation, Writing – review & editing), Chukwuemeka Ikpeazu(Investigation, Writing – review & editing), Gilberto de Lima Lopes, Alexander I. Spira(Investigation, Writing – review & editing), W. Michael Korn(Investigation, Writing – review & editing), Edward S. Kim(Investigation, Writing – review & editing), Stephen V. Liu(Conceptualization, Investigation, Visualization, Writing – review & editing), Hossein Borghaei(Conceptualization, Investigation, Writing – review & editing)
Language: English
Field: Medicine
Open Access status: hybrid
OpenAlex ID: W3201087911
FWCI: 16.28
Cites: 44
Cited by: 238
Related to: 10